Lazard Asset Management’s Day One Biopharmaceuticals DAWN Stock Holding History

Lazard Asset Management’s Portfolio DAWN Stock Details DAWN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-9,364	Closed	-$201K	–	1991
2026 Q1	$201K	Sell	9,364 -13,701	-59%	-$193K	﹤0.01%	1630
2025 Q4	$215K	Buy	23,065 +8,705	+61%	+$72.7K	﹤0.01%	1634
2025 Q3	$101K	Buy	14,360 +595	+4%	+$4.09K	﹤0.01%	1688
2025 Q2	$89K	Buy	+13,765	New	+$94.7K	﹤0.01%	1890

Other funds holding DAWN

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Lazard Asset Management's DAWN Position: Q2 2026 in Review

Lazard Asset Management sold out of Day One Biopharmaceuticals (DAWN) in Q2 2026, closing a stake of 9,364 shares — an estimated $201K sold.

Lazard Asset Management first reported a position in DAWN in Q2 2025 and held it in 4 quarters. The position peaked at $215K in Q4 2025. 1 fund tracked by Wall St. Rank holds DAWN as of Q2 2026.

Lazard Asset Management reported no remaining Day One Biopharmaceuticals position as of Q2 2026 after selling out during the quarter.
Lazard Asset Management sold 9,364 Day One Biopharmaceuticals shares in Q2 2026, an estimated $201K.
Lazard Asset Management first reported a position in Day One Biopharmaceuticals in Q2 2025 and held it in 4 quarters.
Lazard Asset Management's Day One Biopharmaceuticals position peaked at $215K in Q4 2025.
1 fund tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2026.

Based on Lazard Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.